- Home
- CAPR vs RFI Comparison
CAPR vs RFI Comparison
Compare CAPR & RFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- RFI
- Stock Information
- Founded
- CAPR 2005
- RFI 1992
- Country
- CAPR United States
- RFI United States
- Employees
- CAPR N/A
- RFI N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- RFI Investment Managers
- Sector
- CAPR Health Care
- RFI Finance
- Exchange
- CAPR Nasdaq
- RFI Nasdaq
- Market Cap
- CAPR 324.6M
- RFI 323.2M
- IPO Year
- CAPR N/A
- RFI N/A
- Fundamental
- Price
- CAPR $6.28
- RFI $12.10
- Analyst Decision
- CAPR Strong Buy
- RFI
- Analyst Count
- CAPR 8
- RFI 0
- Target Price
- CAPR $24.75
- RFI N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- RFI 69.8K
- Earning Date
- CAPR 08-11-2025
- RFI 01-01-0001
- Dividend Yield
- CAPR N/A
- RFI 8.25%
- EPS Growth
- CAPR N/A
- RFI N/A
- EPS
- CAPR N/A
- RFI N/A
- Revenue
- CAPR $13,392,150.00
- RFI N/A
- Revenue This Year
- CAPR N/A
- RFI N/A
- Revenue Next Year
- CAPR $6,061.53
- RFI N/A
- P/E Ratio
- CAPR N/A
- RFI N/A
- Revenue Growth
- CAPR N/A
- RFI N/A
- 52 Week Low
- CAPR $3.98
- RFI $9.62
- 52 Week High
- CAPR $23.40
- RFI $12.52
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- RFI 52.30
- Support Level
- CAPR $6.17
- RFI $11.89
- Resistance Level
- CAPR $7.30
- RFI $12.07
- Average True Range (ATR)
- CAPR 0.43
- RFI 0.09
- MACD
- CAPR -0.11
- RFI 0.01
- Stochastic Oscillator
- CAPR 4.53
- RFI 60.71
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.